Intervacc Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jonas Sohlman

Amministratore delegato

SEK 1.1m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.3yrs
Proprietà del CEO	n/a
Durata media del management	4.6yrs
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jonas Sohlman (59 yo)

1.3yrs

Mandato

SEK 1,070,000

Compensazione

Mr. Jonas Sohlman served as Chief Financial Officer of Simris Alg AB (publ) since April 1, 2019. Mr. Sohlman serves as Chief Executive Officer of Intervacc AB (publ) since February 28, 2024. He served as A...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jonas Sohlman	Chief Executive Officer	1.3yrs	SEK 1.07m	Nessun dato
Jan Persson	Chief Financial Officer	4.8yrs	Nessun dato	0.056% € 9.2k
Patrik Hellberg	Chief Investment Officer	7.8yrs	Nessun dato	0.025% € 4.2k
Andrew Waller	Chief Scientific Officer	4.4yrs	Nessun dato	0.0037% € 612.9

4.6yrs

Durata media

Gestione esperta: Il team dirigenziale di 2E9 è considerato esperto (durata media dell'incarico 4.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sven Bjorklund	Independent Chairperson	less than a year	SEK 28.00k	2.44% € 404.0k
Mathias Uhlen	Director	less than a year	Nessun dato	Nessun dato
Jan-Ingmar Flock	Independent Director	less than a year	SEK 13.00k	0.36% € 58.8k
Emil Billbäck	Director	less than a year	Nessun dato	Nessun dato
Lisen Fredricson	Independent Director	less than a year	SEK 13.00k	Nessun dato
Lennart Johansson	Independent Director	less than a year	SEK 13.00k	Nessun dato
Camilla McCarthy	Independent Director	less than a year	SEK 13.00k	Nessun dato

1.0yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 2E9 non è considerato esperto (durata media del mandato 1 anni), il che suggerisce un nuovo consiglio.

Intervacc Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings released: kr1.69 loss per share (vs kr1.28 loss in FY 2022)

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

New major risk - Shareholder dilution

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.13 loss in 1Q 2021)

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings released: kr0.59 loss per share (vs kr0.55 loss in FY 2020)

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Forecast to breakeven in 2022

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

Forecast breakeven pushed back to 2023

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

Independent Director recently sold €2.9m worth of stock

New 90-day high: €7.54

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: €5.55

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac

Third quarter 2020 earnings released: kr0.13 loss per share

New 90-day high: €3.91

New 90-day high: €3.57

First half earnings released

New 90-day high - €3.43

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media